AdaptHealth Corp. (AHCO) News & EventsAHCONews & EventsAdaptHealth Corp.

Major Averages Surge Again, Tech Shares Lead Gains

The major averages were sharply higher once again, building on Monday's gains as technology shares continue to lead gains and oil prices continue to drop. Strong quarterly reports from big firms such as Palantir, Caterpillar, and McDonald's helped fuel broad increases, while optimism remains over a U.S.-Iran deal to reopen the Strait of Hormuz potentially on the horizon.Meanwhile, investors are also monitoring reports that the Trump administration is drafting restrictions on certain Chinese-made data center networking components over national security concerns, a move that could have implications for AI infrastructure and semiconductor supply chains.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Palantirprovided areport for Q2Caterpillarreportedand provided its outlook for Q3 and FY26 revenueMcDonald'sreported, while global comparable sales rose 1.3% year-over-yearPfizerreported better-than-expected Q3 earnings and revenue andMerckreportedbut lowered its FY26 earnings outlook2. WALL STREET CALLS:Deutsche BankPalantirto Buy after "exceptional" Q2JPMorganNiketo Underweight on below-consensus estimatesOppenheimerInspire Medicaldespite "noisy" fundamentalsWalmartto Perform at OppenheimerJPMorganPVHto Underweight on estimate risk3. AROUND THE WEB:A Senate report alleges Deutsche Bankand Bank of Americafailed to timely report hundreds of millions of dollars in suspicious transactions linked to Jeffrey Epstein-related accounts, calling for investigations and tougher penalties for compliance failures, Bloomberg reportsApplehas launched a legal complaint at the Investigatory Powers Tribunal over the UK's latest attempt to create a "backdoor" that would allow it to access encrypted customer data, FT saysAnthropic has secured a $10B computing capacity agreement with Nvidia-backed Volta Infra to expand data center access and meet rising demand for its Claude AI products, Bloomberg reportsThe Trump administration has invited staffers from OpenAI, Google, Anthropic, and others to the White House on Tuesday to review the AI oversight framework, The Information saysA review by the New York Times of a dozen lawsuits against Uberby riders that were sexually assaulted or harassed on their rides found the company will scour women's private communications, medical records, and past assaults, using this information to present the women as unreliable narrators of the incidents4. MOVERS:Backblazehigher after, providing guidance for Q3, raising its outlook for FY26, and registering to sell 4.19M shares of stockAmeresco (AMRC) increases after, providing guidance for FY26, and after BNP Paribas upgraded the stock to OutperformPaymentusand Wayfairgain afterClearPoint Neurofalls afterand cutting its guidance for FY26AdaptHealthand Brukerlower after5. EARNINGS/GUIDANCE:Syscoand provided guidance for FY27Shoals Technologies, with EPS and revenue beating consensusBellRing Brandsand raised its outlook for FY26Centurithat CEO Christian Brown said "reflect tremendous year-over-year growth"Graingerand raised its guidance for FY26INDEXES:Near midday, the Dow was up 922.33, or 1.73%, to 54,100.74, the Nasdaq was up 529.64, or 2.04%, to 26,443.54, and the S&P 500 was up 111.50, or 1.47%, to 7,712.00.

Company Revises FY2026 Financial Guidance to $2.85B-$2.89B

Consensus $3.49B. The company said, "The Company is revising its financial guidance for fiscal year 2026 on a continuing operations basis, which excludes the Diabetes Health business, except for free cash flow, which includes the cash flows from continuing operations and discontinued operations, as follows: Net revenue of $2.85 billion to $2.89 billion Adjusted EBITDA of $490 million to $520 million Free cash flow of $80 million to $120 million Relative to our prior fiscal year 2026 Adjusted EBITDA guidance of $680 million to $730 million, the revised guidance includes a $100 million impact from reporting the Diabetes Health business as discontinued operations, including $60 million of previously allocated corporate overhead that will remain in continuing operations, of which the Company expects roughly half to be eliminated within 12 months thereafter. The revised guidance also includes a $55 million impact related to our West Coast capitated contract; a $30 million impact from a manufacturer price increase; and a $15 million impact from other portfolio actions."

AdaptHealth Reports Q2 Revenue of $740.3M, Lowers Full-Year Outlook

Reports Q2 revenue $740.3M vs. $657.1M last year. "In the second quarter, we delivered 15.9% organic growth, with record volume gains across the business," said Suzanne Foster, Chief Executive Officer. "Also, in July we signed a definitive agreement to divest our Diabetes Health business, the most significant step yet in our multi-year effort to focus AdaptHealth on our core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses. Our West Coast capitated partnership reached full scale in the quarter, and the complexity of that transition has impacted our margins. Together with an unexpected price increase from one of our manufacturers, this has led us to lower our full-year outlook. We are moving quickly to address the cost pressures introduced by our rapid growth, and we believe these actions will make us a stronger, more efficient company."